Newcastle-based healthcare innovator SkinBioTherapeutics has significantly narrowed its annual losses and is forecasting a major revenue boost for 2026, powered by a landmark retail partnership.
Financial Performance and Strategic Acquisitions
The firm, headquartered at The Core in Newcastle Helix, published its results for the year ending June 2025. It revealed a dramatic surge in revenue, which climbed from £1.2 million to £4.6 million. Concurrently, its operating losses were more than halved, falling from £2.9 million to £1.1 million.
Company leaders attributed this strengthened financial position to the ongoing success of its AxisBiotix-Ps product and a full year of trading from Dermatonics, a business it acquired in the previous year. The Dermatonics brand, which specialises in treatments for dry skin, warts, and verrucas, saw its own revenue jump from £1 million to £2.2 million, with EBITDA rising sharply from £100,000 to £500,000.
Further bolstering its portfolio, SkinBioTherapeutics acquired Bio-Tech Solutions Ltd (BTS) in October 2024. BTS contributed revenues of £1.4 million and EBITDA of £100,000. The performance of both acquired companies was noted as slightly below expectations due to the timing of customer orders.
The Superdrug Partnership: A High Street Breakthrough
A pivotal moment for the company came in June 2025, when it signed an exclusive commercial contract with health and beauty retail giant Superdrug. The deal involves selling its AxisBiotix-Ac food supplement, designed for irritation-prone and blemish-prone skin, across the retailer's UK stores.
The initial phase saw the product launched in approximately 180 Superdrug stores nationwide. A full, phased roll-out to the remainder of Superdrug's estate is scheduled to begin in Spring 2026. Executives stated that meeting the stringent deadlines for this launch has given the company strong confidence in its growth trajectory for the coming year.
Confident Outlook for Future Growth
The company's cash position was also strengthened significantly, rising to £4.8 million from £800,000, following a share placing. This financial cushion hints at the potential for further strategic acquisitions in the future.
CEO Stuart Ashman commented on the year's progress, highlighting the strengthened relationship with ingredients supplier Croda, which led to the global launch of the SkinBiotix technology under the Zenakin brand name. He emphasised that the benefits of major partnerships and acquisitions take time to fully materialise at the group level.
"We have seen a great start to FY26 and anticipate another year of growth from direct and indirect sales," said Ashman. "We are especially looking forward to seeing a new generation of cosmetics products with Zenakin included and further high street exposure for AxisBiotix as the Superdrug nationwide roll-out continues."
With its products now on high street shelves and a robust pipeline, SkinBioTherapeutics is positioning itself for a transformative period, aiming to convert its innovative science into sustained commercial success.
